Tandem Diabetes Care (MEX:TNDM) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Tandem Diabetes Care EBITDA Margin % Related Terms
Tandem Diabetes Care EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:TNDM vs CNMD, AORT, LMRI: EBITDA Margin % Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (MEX:TNDM) has a EBITDA Margin % of -5.56% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tandem Diabetes Care and its competitors. According to the industry distribution chart, Tandem Diabetes Care ranks #549 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 67.2%.
Is Tandem Diabetes Care's EBITDA Margin % too high?
Tandem Diabetes Care's current EBITDA Margin % is -5.56%. Based on the distribution chart, Tandem Diabetes Care ranks #549 out of 817 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Tandem Diabetes Care has a GF Score™ of 66/100, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's EBITDA Margin % compare to CNMD and AORT?
According to the Medical Devices & Instruments industry distribution chart, Tandem Diabetes Care ranks #549 out of 817 companies for EBITDA Margin %. This places Tandem Diabetes Care in the lower half of its industry. The industry median EBITDA Margin % is 7.44. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.44, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Tandem Diabetes Care and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tandem Diabetes Care's current EBITDA Margin % is -5.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Tandem Diabetes Care (MEX:TNDM) has a current EBITDA Margin % of -5.56%. The stock's GF Value™ is MXN1,446.01, compared to a current price of MXN745.00 — trading 48.5% below its estimated fair value. The current EBITDA Margin % is -5.56%. Tandem Diabetes Care's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Tandem Diabetes Care (MEX:TNDM), the current EBITDA Margin % is -5.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (MEX:TNDM) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of MXN745.00 is trading 48.5% below its estimated GF Value™ of MXN1,446.01.
Key valuation signals for MEX:TNDM:
EBITDA Margin %: -5.56%
GF Value™: MXN1,446.01 vs. price of MXN745.00 (48.5% below fair value)
No single metric tells the full story. See the MEX:TNDM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
66GF Score
Get the complete analysis for MEX:TNDM
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:TNDM has been successfully added to your 
